Aging-Related Diseases Archives - Sanford Burnham Prebys

Dr. Piña-Crespo earned a PhD in Pharmacology from University College London (UCL), England under the supervision of Profs. Alasdair Gibb & David Colquhoun FRS. He completed postdoctoral training as a Pew Fellow/Research Associate with Prof. Steve Heinemann in the Molecular Neurobiology Laboratory at The Salk Institute, La Jolla, California. Dr. Piña-Crespo has held faculty positions as Instructor and Assistant Professor at Universidad Centroccidental, Venezuela and as Lecturer in the Biology Department at the University of San Diego, California.

Education and Training

  • Postdoctoral training (Pew Fellow/Research Associate) The Salk Institute, California
  • PhD in Pharmacology University College London (University of London), England
  • Veterinarian (D.V.M.) Universidad Centroccidental Lisandro Alvarado, Venezuela

Honors and Recognition

Pew Fellow in the Biomedical Sciences

Neuroscience Discovery Research

Select Publications

Showing 1 of 1

Dr. Anne Bang is an experienced cell biologist and stem cell expert who leads efforts at the Prebys Center to develop patient cell specific and human induced pluripotent stem cell (hiPSC)-based disease models for drug screening and target identification. Dr. Bang has over 20 years of experience in the fields of developmental and stem cell biology. She obtained a BS degree from Stanford University, a PhD in Biological Sciences from the University of California, San Diego, and did postdoctoral training in the Neurobiology Laboratory at the Salk Institute for Biological Sciences where her studies focused on nervous system development. 

Anne’s experience in stem cell biology began in 2005 when she joined ViaCyte, Inc. where she served as Director of Stem Cell Research and managed an interdisciplinary group working to develop human embryonic stem cells as a replenishable source of pancreatic cells for the treatment of diabetes. Her efforts focused on optimization of the differentiation process, and then on advancing the cell therapy product into development, scaled manufacturing, product characterization, and safety assessment. Anne is a co-inventor on multiple ViaCyte patents, and her team’s contributions played a key role in securing a $20 MM California Institute of Regenerative Medicine (CIRM) Award. 

In June of 2010, Sanford Burnham Prebys recruited Anne as Director of Cell Biology to lead efforts in stem cell-based disease modeling at the Conrad Prebys Center for Chemical Genomics. Her role includes leading internal research projects, as well as external collaborations with academic and industry partners.  Anne’s research program is primarily focused on neurological and neuromuscular disease, with the aim of designing human cell-based models and assays that recapitulate disease phenotypes, yet have the throughput and reproducibility required for drug discovery. Towards this goal her group has worked to develop a suite of foundational high throughput assays to monitor neuronal morphology, mitochondrial function, and electrophysiology, using high content screening, and multi-electrode array formats. They have conducted high-throughput drug screens on muscular dystrophy patient cells, hiPSC-derived cardiomyocytes, and hiPSC-derived neurons, including from Alzheimer’s patient specific hiPSC. Anne is a principal investigator for the National Institute of Mental Health (NIMH) National Cooperative Reprogrammed Cell Research Groups consortium and has also received research support from rare disease foundations and pharma sponsored collaborations. She also serves on advisory boards for multiple biotechnology companies.

Select Publications

Showing 1 of 1

Malene Hansen received her early training at the University of Copenhagen in Denmark. She received a Master’s degree in Biochemistry in 1998 and a PhD degree in Molecular Biology in 2001. During this time, Dr. Hansen worked as a trainee in several labs in the US, including the University of North Carolina in Chapel Hill, and The Scripps Research Institute, La Jolla. After her Ph.D, Dr. Hansen trained as a postdoctoral fellow in molecular genetics at the University of California in San Francisco. Dr. Hansen received postdoctoral funding from the Danish National Research Councils as well as an Ellison/American Federation of Aging Research Senior Postdoctoral Fellowship. Dr. Hansen was recruited to Sanford-Burnham Medical Research Institute in September 2007.

Awards

2017 National Postdoctoral Association Mentor Award

Select Publications

Showing 3 of 3

Dr. Yu Xin (Will) Wang received his PhD at the University of Ottawa where he identified cellular asymmetry and polarity mechanisms regulating muscle stem cell self-renewal and skeletal muscle regeneration. He then carried out postdoctoral training at Stanford University School of Medicine developing single cell multi-omic approaches to characterize the regenerative process and what goes awry with disease and aging.  

“I’ve always had a passion for science and became fascinated with how the body repairs and heals itself when I was introduced to the potential of stem cells in regenerative medicine. I was struck by the ability of a small pool of muscle stem cells that can rebuild and restore the function of muscle. My lab at Sanford Burnham Prebys aims to better understanding the repair process and harness our body’s ability to heal in order to combat chronic diseases and even counteract aging.”

Education and Training

Postdoctoral Fellowship, Stanford University School of Medicine
PhD in Cellular Molecular Medicine, University of Ottawa, Canada
BS in Biomedical Sciences, University of Ottawa, Canada

Prestigious Funding Awards

2020: NINDS K99/R00 Pathway to Independence Award

Honors and Recognition

Governor General’s Gold Medal – Canada

Select Publications

Showing 2 of 2

Dr. Xiao Tian participates in the Degenerative Diseases Program and the Cancer Genome and Epigenetics Program at Sanford Burnham Prebys. He started his lab in 2024 to understand the fundamental biology of aging and its contribution to age-related diseases. He joined the Institute after his postdoctoral research in Dr. David Sinclair’s lab at Harvard Medical School where he co-wrote the Information Theory of Aging. He obtained his BS from Shandong University and his PhD from the University of Rochester where he worked with Dr. Vera Gorbunova.
 

Education

2018-2023: Postdoc, Harvard Medical School
2016-2018: Postdoc, University of Rochester
2010-2016: PhD, Biology of Aging, University of Rochester
2005-2009: BS, Microbial Technology, Shandong University
 

Honors and Awards

2020-2026: K99/R00 Pathway to Independence Awards, NIH/NIA
2019-2020: NASA Postdoctoral Fellowship, NASA Ames Research Center
2017: Outstanding Dissertation Award for the Natural Sciences, University of Rochester
2015: Messersmith Dissertation Fellowship, University of Rochester
2014: Award for Outstanding Self-Financed Students Abroad, China Scholarship Council
2010-2014: Holtfreter Fellowship, University of Rochester
2007: Weichai Power Scholarship, Shandong University
2006-2008: Excellent Student Scholarship, Shandong University

Select Publications

Showing 2 of 2

Reprogramming to recover youthful epigenetic information and restore vision.

Lu Y, Brommer B, Tian X, Krishnan A, Meer M, Wang C, Vera DL, Zeng Q, Yu D, Bonkowski MS, Yang JH, Zhou S, Hoffmann EM, Karg MM, Schultz MB, Kane AE, Davidsohn N, Korobkina E, Chwalek K, Rajman LA, Church GM, Hochedlinger K, Gladyshev VN, Horvath S, Levine ME, Gregory-Ksander MS, Ksander BR, He Z, Sinclair DA

Nature 2020 Dec ;588(7836):124-129

Related Disease
Aging-Related Diseases, Brain Cancer, Cancer, Childhood Diseases, Immune Disorders, Inflammatory/Autoimmune Disease, Leukemia/Lymphoma

Phenomena or Processes
Adapter Proteins, Adult/Multipotent Stem Cells, Aging, Angiogenesis, Apoptosis and Cell Death, Bcl-2 Family, Cancer Biology, Cancer Epigenetics, Cell Adhesion and Migration, Cell Biology, Cell Cycle Progression, Cell Differentiation, Cell Motility, Cell Proliferation, Cell Signaling, Cell Surface Receptors, Cellular Senescence, Chromosome Dynamics, Combinatorial Therapies, Cytokines, Development and Differentiation, Disease Therapies, DNA Damage Checkpoint Function, Embryonic/Pluripotent Stem Cells, Epigenetics, Gene Regulation, Genomic Instability, Growth Factors, Hematopoiesis, Host Defense, Host-Pathogen Interactions, Inflammation, Innate Immunity, Kinase Inhibitors, Metastasis, Neurogenesis, Oncogenes, Phosphorylation, Posttranslational Modification, Receptor Tyrosine Kinases, Serine/Threonine Kinases, Signal Transduction, TNF-Family, Transcription Factors, Transcriptional Regulation, Tumor Microenvironment, Tumorigenesis, Tyrosine Kinases, Ubiquitin, Ubiquitin Protease System and Ubiquitin-like Proteins

Anatomical Systems and Sites
Brain, General Cell Biology, Hematopoietic System, Immune System and Inflammation, Nervous System

Research Models
Bacteria, Cultured Cell Lines, Human Adult/Somatic Stem Cells, Human Cell Lines, Mouse, Mouse Cell Lines, Mouse Embryonic Stem Cells, Mouse Somatic Stem Cells, Primary Cells, Primary Human Cells

Techniques and Technologies
3D Image Analysis, 3D Reconstructions, Biochemistry, Bioinformatics, Cell Biology, Cellular and Molecular Imaging, Chemical Biology, Computational Biology, Confocal Microscopy, Correlative Light and Electron Microscopy, Drug Delivery, Drug Discovery, Drug Efficacy, Electron Microscopy, Fluorescence Microscopy, Fragment-Based Drug Design, Gene Expression, Gene Knockout (Complete and Conditional), Gene Silencing, Genetics, Genomics, High Content Imaging, High-Throughput/Robotic Screening, In vivo Modeling, Live Cell Imaging, Live Imaging, Mass Spectrometry, Microscopy and Imaging, Molecular Biology, Molecular Genetics, Nucleic Acid Synthesis, Protein-Protein Interactions, Protein-Small Molecule Interactions, Proteomics, Rational Drug Design, RNA Interference (RNAi), Scanning Cytometry, Small Molecule Compounds, Transgenic Organisms, Transplantation

We seek to understand why cancer occurs and what is the Achille’s heel of cancer, and to develop effective therapeutic interventions.

The successful treatment of any disease requires a good understanding of the mechanisms at work. Cancer is fundamentally caused by aberrant gene expression, which reflects the misinterpretation of DNA information at both genetic and epigenetic levels. We are interested in uncovering DNA-related alterations that drive cancer-favored transcriptional programs, identifying cancer-specific vulnerabilities, and developing effective therapeutic interventions for cancer treatment. 

Xueqin Sun’s Research Report

Precise gene expression (the interpretation of DNA) is essential for almost all biological processes, and understanding gene regulation is one of the most pivotal frontiers in biological research under both health and disease circumstances. Gene expression is mainly regulated at genetic (with changes of DNA sequence) and epigenetic (without changing DNA sequence) levels. And gene dysregulation can lead to various health conditions and diseases, including developmental disorders, aging, and cancer. The overarching goal of Sun Lab is to uncover driving genetic and epigenetic alterations involved in cancer, to understand how developmental pathways and aging process impact cancer progression, and to identify mechanisms of action for developing more effective therapeutic strategies.

We are an interdisciplinary lab particularly focused on the following research directions:

  1. The EP400 chromatin remodeling complex
    The EP400 complex is an evolutionarily conserved SWR1-class ATP-dependent chromatin remodeling complex encompassing ~17 components, with a total molecular mass of ~1.5 mega-dalton. The EP400 complex plays critical roles in diverse cellular processes, including chromosome stability, transcription, DNA recombination, DNA damage repair, embryonic stem cell renewal/development, and oncogenesis. The EP400 complex can incorporate histone variants, such as H2AZ and H3.3, into the genome to regulate gene expression. Our recent work discovers BRD8—one of the core subunits of the EP400 complex—as a unique vulnerability of p53 wildtype glioblastoma (GBM), the most prevalent and devastating type of brain cancer. BRD8-driven EP400 complex highjacks H2AZ at p53 target loci to block p53-mediated transactivation and tumor suppression (Nature, 2023). The bromodomain of BRD8 plays the key role in this process. Bromodomain is a druggable domain as evidenced by a number of successful small molecules targeting diverse bromodomains encoded by the human genome across multiple cancer types. Furthermore, findings from others and us suggest that the EP400 complex is involved in different cancers. Thus, we seek to unravel the roles of the EP400 complex in health and disease, and to better understand how to target the EP400 complex for developing effective therapeutic interventions.
  2. The NuRD chromatin remodeling complex
    The NuRD complex is also a highly conserved class of ~ 1 MDa multi-subunit chromatin remodeling complexes that consume energy derived from ATP hydrolysis to remodel the configuration of chromatin to control gene transcription programs, with a primary role in gene silencing. Chromatin remodeling is vital for efficiently framing the cellular response to both intrinsic and extrinsic signals and has enormous implications for determining cellular states. NuRD complex is unique in combining ATP-dependent chromatin remodeling, protein deacetylase activity, and recognition of methylated DNA and histone modifications, and has multifarious roles in chromatin organization, transcription regulation, and genome maintenance; thereby, largely impacts health and disease. The NuRD complex has been in the central stage of brain development studies, and is significantly related to brain disorders/diseases. Interestingly, NuRD complex re-assembles by exchanging the chromatin remodeling subunits CHD3/4/5 to achieve specific regulation of an array of genes required for generating distinct cell types in a highly organized manner, especially over brain development. Amongst the genes encoding NuRD complex components, CHD5 is located in human chromosome 1 short arm (1p36), a region that is frequently hemizygously deleted in diverse cancers. Besides genetic deletion, CHD5 is also often silenced in cancer cells due to epigenetic mechanisms, such as promoter hypermethylation, aberrant expression of other chromatin regulators, and microRNAs-mediated translational repression and/or mRNA instability. Our current work seeks to determine whether and how CHD5-driven NuRD complex is involved in tumorigenesis (In preparation, 2024). We will further understand how NuRD complex is involved in both development and tumorigenesis, and identify mechanism of action to develop rational therapeutic strategies.
  3. Novel genetic and epigenetic underpinnings in GBM
    GBM is notorious for being a highly complex and plastic cancer type. However, at the genetic level, GBM harbors a relatively low genetic alteration burden compared to the majority of other cancers from pan-cancer profiling studies. This indicates the largely undocumented epigenetic mechanisms that interplay with genetic alterations and co-reprogram transcriptional networks essential for GBM development. Epigenetic changes are usually reversible by nature, as evidenced by numerous successes in targeting epigenetic regulators using small chemical compounds. As actionable therapeutic targets for GBM have been scarce, we are keen to uncover novel epigenetic pathways underlying gliomagenesis under different genetic backgrounds, which will potentially provide promising therapeutic opportunities for GBM treatment.
  4. Novel GBM mouse models
    Despite decades of effort, our knowledge about GBM biology is still very limited. GBM harbors a number of genetic alterations. However, among these recurrent genetic lesions, only several have been implicated in gliomagenesis, with most being undocumented. Moreover, the mechanisms by which these genetic alterations are involved in establishing GBM-favored epigenetic landscapes and transcription programs during GBM progression are still largely elusive. The lack of efficient approach to establish mouse models for investigating gene function in gliomagenesis and the limit of current mouse models to recapitulate clinical GBM features in brain is the prime reason that hinders GBM biological research. To this end, we have developed an engineered neural stem cells (NSCs)-based strategy to rapidly generate highly aggressive GBM with desired genetic lesions (genotypes) in mouse brain. Therefore, we will further optimize this strategy to establish a series of novel mouse models possessing recurrent combinations of genetic alterations (genotypes) in GBM, in order to systematically study whether and how these genetic lesions are involved in gliomagenesis and identify genotype-specific dependencies.
  5. Crosstalk between GBM cells and tumor microenvironment
    GBM exhibits highly diffuse and infiltrative nature, which contributes to therapeutic resistance and tumor relapse after surgical removal, resulting in dismal prognosis. A better understanding of gliomagenesis involving not only malignant cells themselves, but also the holistic bidirectional interactions of malignant cells with a variety of proximal and distal cells within the organism, is profound for developing novel effective therapies to improve GBM prognosis. Individual invasive GBM cells intermingle with normal brain cells and often cause relapse in brain areas essential for patient survival. Emerging evidence indicates that glioma cells highjack normal brain cells to thrive, and even transform them. However, how gliomagenesis reshapes ecological composition/landscape in host brain and how brain microenvironment affects gliomagenesis are still largely unclear. By using our novel highly invasive mouse models that recapitulate the multiforme diffuse topographies of GBM in brain, we seek to understand the interactions between GBM cells and brain microenvironment, and identify extrinsic pathways that are essential for GBM progression and migration.


Our lab is focused on both fundamental questions in cancer biology and translation of promising therapeutic strategies.

To achieve these, we work together with many fantastic collaborators to develop and leverage cutting-edge technologies, including but not limited to, high-throughput functional genomics (CRISPR/Cas9 screens, exon tiling scan, targeted mutagenesis, etc.), cell and molecular biology, genomics, epigenomics, proteomics, biochemistry, microscopy (2D/3D, time-lapse, two-photon, light sheet, etc.), automated large-scale drug synthesis/screening, structural biology, single cell and spatial multi-omics, artificial intelligence, and bioinformatics. We also establish novel patient-derived models and novel mouse models to facilitate our research programs. Our ultimate goals are to better understand fundamental genetic and epigenetic apparatuses involved in cancer-specific transcriptional networks, provide more effective therapeutic opportunities, and contribute to shifting the paradigms in cancer treatment and precision medicine.

Select Publications

Showing 2 of 2

Pier Lorenzo Puri earned his MD at the University of Rome “la Sapienza” in 1991. Dr. Puri completed his internship in Internal Medicine at the hospital “Policlinico Umberto I” (Rome) from 1992 to 1997, and defended an experimental thesis on the vascular effects of angiotensin II to graduate as Specialist in Internal medicine at the University of Rome “la Sapienza” in 1997. During this time he was frequently working at the Freien University of Berlin, as visiting scientist at the Deprtment of Biochemistry and Molecular Biology, to perform experiments of protein and DNA microinjection in cultured cells. Dr. Puri trained as a post-doctoral fellow at the University of California San Diego (UCSD), in the department of Cell Biology, under the supervision of Dr. Wang, from 1997 to 2001. He was appointed as Staff Scientist at the Salk Institute (La Jolla) in 2001, and became an Assistant Telethon Scientist at the Dulbecco Telethon Institute in Rome in 2002. He was upgraded to Associate Telethon Scientist at the Dulbecco Telethon Institute in Rome since 2007 and became Senior Telethon Scientist, Dulbecco Telethon Institute, in 2012, but declined this position. Dr. Puri joined Sanford Burnham Prebys as an Assistant Professor in 2004. He has been promoted to Associate Professor in 2010 and full Professor in 2015. From 2008 to 2016 Dr. Puri served as Adjunct Professor of Pediatrics at the University of California, San Diego. From 2008 to 2013 Dr Puri was an Associate Member of Sanford Children’s Health Research Center. Dr Puri has been Director of the laboratory of Epigenetics and Regeneration at Fondazione S. Lucia, Roma, Italy, but stepped down this position since 2019.

Education

University of California San Diego, Postdoctoral, Department of Biology
University of Rome La Sapienza, PhD, Internal Medicine
University of Rome La Sapienza, MD, Internal Medicine
University of Rome La Sapienza, Undergraduate, Internal Medicine

Other Appointments

2020-2024: Member of the Science Advisory Board (SAB) European Commission-funded Consortium BIND (Brain Involvement In Dystrophinopathies)
2015-2019: Standing Member, NIH Study Section (SMEP)
2010-present: Member of Editorial Board of Skeletal Muscle

Select Publications

Showing 2 of 2

After a successful teaching career at the University of Michigan I have had the privilege to “reboot” my research career at Sanford Burnham Prebys where I have had the opportunity to develop novel methodologies to understand cardiomyopathy. I have also had the opportunity to work with NASA scientists to do experiments on the International Space Station.

Education

Postdoctoral Fellow, Stanford University, Palo Alto, CA, Neurochemistry
Postdoctoral Fellow, University of Texas Medical School, Houston, TX, Neuroscience NIMH 
PhD, Wesleyan University, Middletown, CT, Neuroscience NIMH 
B.A., Lehigh University, Bethlehem, PA, Biology 

Prestigious Runding Awards or Major Collaborative Grants

2015-2020: NIH R01 HL132241-01A1 – Using Drosophila genetics to identify molecular links between ion channel dysfunction and pathological cardiac remodeling. (PI) 2013-2018 NASA NRA #NNH12ZTT001N – The effects of microgravity on cardiac function, structure and gene expression using the Drosophila model. (Co-I)

Honor and Awards

2014: Space Florida International Space Station Research Competition Winner – Co-investigator – One of three Basic Research proposals selected for launch aboard SpaceX3 – Mission completed, live flies returned on May 18,2014
2001: Excellence in Teaching Award, University of Michigan
1997: Excellence in Teaching Award, University of Michigan
1986-1988: National Institute of Mental Health Fellowship
1983-1985: National Institute of Mental Health Fellowship
1981: Sigma Xi Research Award 1980 MBL Scholarship, Neural Systems and Behavior Course
1971-1975: National Merit Scholarship, Lehigh University

Board Appointments

2018-present: Board member American Society for Gravitational and Space Research

Select Publications

Showing 2 of 2

Dr. Kumsta earned her degree as a Diplom Biologist/M.Sc. and PhD from the Technical University of Munich, Germany. She performed her thesis research in the laboratory of Dr. Ursula Jakob at the University of Michigan. Dr. Kumsta joined Sanford Burnham Prebys and the lab of Malene Hansen as a postdoctoral fellow in 2009. In 2018 Caroline was promoted to Research Assistant Professor and then to Assistant Professor in 2021.

Education and Training

2018-2021: Research Assistant Professor
2016-2018: Staff Scientist, Development, Aging and Regeneration, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, California, USA
2009-2016: Postdoctoral Fellow with Dr. Malene Hansen, Development, Aging and Regeneration, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, California, USA
2009: Postdoctoral Associate with Dr. Ursula Jakob, Department of Molecular, Cellular and Developmental Biology, University of Michigan, Ann Arbor, USA
2005-2008: Doctor rerum naturalium (PhD), magna cum laude Technical University of Munich, Germany Thesis research performed in the laboratory of Dr. Ursula Jakob at the University of Michigan, Ann Arbor, USA
1999-2005: Diplom-Biologin Univ. (MS), with honors Technical University of Munich, Germany

Honors and Recognition

2015: Winner of the Biochemical Journal Best Oral Presentation Prize at the EMBO Workshop: The Regulation of Aging and Proteostasis
2013: Winner of award for the best oral presentation at the 12th Annual Poster Symposium at Sanford Burnham Prebys Medical Discovery Institute
2012: Invitation and sponsorship from the Bavarian government to attend the first “Return to Bavaria” conference in Munich, Germany
2011: Recipient of the 2011 career development award “Lenka Musafia Finci Award” in recognition for outstanding research with great potential to help mankind from the Fishman Fund at Sanford Burnham Prebys Medical Discovery Institute
2011: Grant from Boehringer Ingelheim Fonds to attend the conference Protein Synthesis and Translational Control, Heidelberg, Germany
2008: Full fellowship from the Ellison Medical Foundation to attend Molecular Biology of Aging Laboratory Course, MBL, Woods Hole, MA
2007: Grant from BIF to attend the conference Biology of Aging, Stockholm, Sweden
2006-2008: PhD Fellowship from Boehringer Ingelheim Fonds 
2006: Grant from BIF to attend the conference Molecular Genetics of Aging, Cold Spring Harbor, NY
2004: Diploma Thesis Fellowship from the Bayerische Forschungsstiftung (Bavarian Research Foundation)

Select Publications

Showing 1 of 1

Gregg Duester earned his PhD in Microbiology from the Medical College of Virginia in Richmond in 1982. He received postdoctoral training at the University of California at Irvine and worked as Assistant Research Professor at that institution. Dr. Duester was appointed Assistant Professor in the Department of Biochemistry at Colorado State University at Fort Collins; he was recruited to Sanford Burnham Prebys Medical Discovery Institute in 1991. 

Education

1982-1985: Postdoctoral Training, University of California, Irvine, Molecular Genetics
1982: PhD, Medical College of Virginia, Richmond, Microbiology
1976: BS, Colorado State University, Fort Collins, Zoology 

Honors and Recognition

2006: Outstanding Basic Health Sciences Alumnus Award, Medical College of Virginia
1989-1991: NIH Research Scientist Development Award
1982-1985: NIH Postdoctoral Fellowship Award
1981: John C. Forbes Graduate Student Research Achievement Award 

Other Affiliations

Editorial Board for Developmental Biology
Editorial Board for Developmental Dynamics

Select Publications

Showing 1 of 1